Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Leukemia, Myeloid, Acute 191Anemia, Refractory, with Excess of Blasts 179Myelodysplastic Syndromes 175Leukemia 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Neoplasms 121Multiple Myeloma 116Venous Thromboembolism 111Anemia 108Leukemia, Myelomonocytic, Chronic 103Leukemia, Lymphocytic, Chronic, B-Cell 100Myeloproliferative Disorders 99Lymphoma, Non-Hodgkin 97Lymphoma 96Hodgkin Disease 85Thrombocytopenia 84Anemia, Aplastic 79Primary Myelofibrosis 67Lymphoma, Follicular 67Hematologic Neoplasms 63Leukemia, Myeloid, Chronic-Phase 61Lymphoma, Mantle-Cell 59Febrile Neutropenia 59Congenital Abnormalities 59Neoplasms, Plasma Cell 57Leukemia, Myeloid, Accelerated Phase 57Anemia, Refractory 57Leukemia, Myelogenous, Chronic, BCR-ABL Positive 56Blast Crisis 56Burkitt Lymphoma 53

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Clonal Cytopenia of Undetermined Significance × Classical hematology × Clear all
NCT05102370 2026-01-27

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
4 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡